Replies to post #251495 on Biotech Values

[iwfal]

Price them both the same and office makes $34 more profit with Daxxify.

Yes, this is the chief weakness for EOLS with this data. Over/under that they change this when they start being impeded by Daxxy? (Reasonable chance their Q1/Q4 neuromod revenues are better than RVNC’s ratio of same, if so this isn’t an issue for EOLS. Yet)